Dariusz Dudek

Bivalirudin during primary PCI in acute myocardial infarction.

B. Gersh, S. Pocock, G. Stone, 2008, The New England journal of medicine.

Randomized Trial of Atopaxar in the Treatment of Patients With Coronary Artery Disease: The Lessons From Antagonizing the Cellular Effect of Thrombin–Coronary Artery Disease Trial

D. Angiolillo, M. O’Donoghue, S. Wiviott, 2011, Circulation.

Universal definition of myocardial infarction.

Jeroen J. Bax, Joseph S Alpert, Kristian Thygesen, 2007 .

Randomized Trial of Atopaxar in the Treatment of Patients With Coronary Artery Disease: The Lessons From Antagonizing the Cellular Effect of Thrombin–Coronary Artery Disease Trial

Deepak L. Bhatt, M. Flather, D. Dudek, 2011, Circulation.

Ticagrelor With or Without Aspirin Following Percutaneous Coronary Intervention in High-Risk Patients With Concomitant Peripheral Artery Disease: a subgroup analysis of the TWILIGHT randomized clinical trial.

G. Dangas, U. Baber, B. Vogel, 2024, American heart journal.

Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention.

G. Dangas, G. Weisz, U. Baber, 2023, JACC. Cardiovascular interventions.

Clinically Driven Revascularization in High-Risk Patients Treated With Ticagrelor Monotherapy After PCI: Insights from the Randomized TWILIGHT Trial.

Samin K. Sharma, G. Dangas, S. Mehta, 2023, The American journal of cardiology.

Frequency and Predictors of Stent Thrombosis After Percutaneous Coronary Intervention in Acute Myocardial Infarction the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial Investigators

G. Dangas, H. Parise, G. Guagliumi, 2011 .